Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Brensocatib Prior Auth | OpenPa…
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Brensocatib Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and quantity-limit approval for Brinsupri (brensocatib) 10 mg and 25 mg tablets for Boeing commercial members. It establishes initial and renewal clinical criteria, quantity-limit exception criteria, and 12-month approval periods.

    Policy Summary
    PayerPrime Therapeutics
    PolicyBrensocatib Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionProvide clinical documentation supporting the bronchiectasis diagnosis, CT confirmation, and qualifying antibiotic-treated pulmonary exacerbation history.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    10 mg / 25 mgCovered tablet strengths
    30Quantity limit per strength
    30 daysQuantity-limit day supply
    12 monthsApproval duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2
    Adult exacerbation threshold

    Coverage Criteria

    Initial Therapy Criteria

    Initial target-agent approval requires all of the following.

    Initial therapy

    • Approved indication

      • Non-cystic fibrosis bronchiectasis

        • Clinical history is consistent with bronchiectasis, such as cough, chronic sputum production, or recurrent respiratory symptoms.
        • Diagnostic confirmation: Computed tomography has confirmed the diagnosis of bronchiectasis.
        • Exacerbation history

          • General exacerbation threshold: At least two pulmonary exacerbations requiring an antibiotic prescription within the past 12 months.2 exacerbations in 12 months
          • Pediatric exacerbation threshold: The patient is pediatric and has had at least one pulmonary exacerbation requiring an antibiotic prescription within the past 12 months.1 exacerbation in 12 months
        • Excluded conditions absent: The patient does not have cystic fibrosis, primary or secondary immunodeficiency, non-tuberculous mycobacterial disease, allergic bronchopulmonary aspergillosis, or tuberculosis.
      • Other FDA-labeled indication: The patient has another FDA-labeled indication for the requested agent and route of administration, and the patient's age is within FDA labeling or there is support for use at the patient's age for the requested indication.
    • Specialist involvement: The prescriber is a specialist in the area of the patient's diagnosis, such as a pulmonologist, or has consulted with a specialist.
    • Contraindications: The patient does not have any FDA-labeled contraindications to the requested agent.

    Continuation Therapy Criteria

    Renewal target-agent approval requires all of the following.

    Continuation therapy

    • Previous approval: The patient has been previously approved for the requested agent through the plan's Prior Authorization process.

      Patients not previously approved for the requested agent require initial evaluation review.

    • Clinical benefit: The patient has had clinical benefit with the requested agent.
    • Specialist involvement: The prescriber is a specialist in the area of the patient's diagnosis, such as a pulmonologist, or has consulted with a specialist in the area of the patient's diagnosis.
    • Contraindications: The patient does not have any FDA-labeled contraindications to the requested agent.

    Quantity-Limit Criteria

    The quantity limit will be approved when one of the following is met.

    Quantity-limit approval

    • Within program limit: The requested quantity does not exceed the program quantity limit.30 tablets per 30 days
    • Higher dose without maximum FDA dose: The requested quantity exceeds the program quantity limit, the requested indication has no maximum FDA-labeled dose, and there is support for therapy with a higher dose for the requested indication.
    • Cannot use lower quantity of higher strength: The requested quantity exceeds the program quantity limit, does not exceed the maximum FDA-labeled dose for the requested indication, and there is support for why the requested quantity cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit.

    Coverage is available for non-cystic fibrosis bronchiectasis when the diagnosis is confirmed by computed tomography and the patient has the required pulmonary exacerbation history: at least two exacerbations requiring an antibiotic prescription within the past 12 months, or, for a pediatric patient, at least one such exacerbation within the past 12 months. Coverage may also be considered for another FDA-labeled indication for the requested agent and route of administration when the patient's age is within labeling or supporting evidence is provided for use at that age.

    The non-cystic fibrosis bronchiectasis pathway does not qualify when the patient has cystic fibrosis, primary or secondary immunodeficiency, non-tuberculous mycobacterial disease, allergic bronchopulmonary aspergillosis, or tuberculosis. The prescriber must be a specialist in the area of the diagnosis, or have consulted with a specialist, and the patient must have no FDA-labeled contraindication to the requested agent.

    Initial Therapy Criteria

    Continuation Criteria

    Brensocatib Renewal

    Renewal brensocatib authorization requires all of the following.

    Brensocatib renewal

    • Previous approval: The patient has been previously approved for the requested agent through the plan's Prior Authorization process.
    • Clinical benefit: The patient has had clinical benefit with the requested agent.
    • Specialist involvement: The prescriber is a specialist in the area of the patient's diagnosis, such as a pulmonologist, or has consulted with a specialist in the area of the patient's diagnosis.
    • Contraindications:

    Clinical and Program Parameters

    Adult pulmonary exacerbations
    Minimum exacerbationsAt least two pulmonary exacerbations
    Antibiotic requirementEach exacerbation must require an antibiotic prescription
    Lookback periodWithin the past 12 months
    Pediatric pulmonary exacerbations
    Minimum exacerbationsAt least one pulmonary exacerbation
    Patient populationPediatric patient
    Antibiotic requirementThe exacerbation must require an antibiotic prescription

    Quantity Limits

    Brinsupri (brensocatib) 10 mg tablets
    Strength10 mg tablets
    Covered quantity limit30 tablets
    Day supply30 days
    Brinsupri (brensocatib) 25 mg tablets
    Strength25 mg tablets
    Covered quantity limit30 tablets
    Day supply30 days

    Provider Actions and Documentation

    Prior Authorization

    Initial Authorization Required

    Initial authorization requires prior approval through the plan’s Prior Authorization process. The requested agent must meet an approved FDA-labeled indication and all applicable clinical, age, specialist, and contraindication requirements.

    • For non-cystic fibrosis bronchiectasis, document the diagnosis, qualifying clinical history, CT confirmation, required pulmonary exacerbations, and absence of specified exclusionary conditions.
    • For another FDA-labeled indication, document the indication and route of administration, age support, specialist involvement or consultation, and absence of FDA-labeled contraindications.
    Prior Authorization

    Renewal Authorization Requirements

    Renewal authorization requires evidence that the patient was previously approved for the requested agent through the plan’s Prior Authorization process and has experienced clinical benefit with the agent.

    • Patients without prior plan approval require initial evaluation review.
    • Renewal also requires specialist prescribing or specialist consultation and confirmation that the patient has no FDA-labeled contraindication to the requested agent.

    Policy Background

    This policy addresses prior authorization and quantity-limit review for Brinsupri (brensocatib) tablets in the treatment of non-cystic fibrosis bronchiectasis or another FDA-labeled indication for the requested agent and route of administration. For the bronchiectasis pathway, documentation must establish a compatible clinical history, computed tomography confirmation, and a recent history of antibiotic-treated pulmonary exacerbations.

    The policy also supports review of age-specific use for other FDA-labeled indications, specialist involvement or consultation, and the absence of FDA-labeled contraindications. Continued therapy and requests that exceed the standard quantity limit are evaluated separately under the applicable renewal and quantity-limit requirements.

    Policy Summary
    PayerPrime Therapeutics
    PolicyBrensocatib Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionProvide clinical documentation supporting the bronchiectasis diagnosis, CT confirmation, and qualifying antibiotic-treated pulmonary exacerbation history.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation CriteriaClinical and Program ParametersQuantity LimitsProvider Actions and DocumentationPolicy Background
    Exceeds maximum FDA dose: The requested quantity exceeds the maximum FDA-labeled dose for the requested indication and there is support for therapy with a higher dose for the requested indication.
    The patient does not have any FDA-labeled contraindications to the requested agent.
    Lookback periodWithin the past 12 months
    Program quantity limit
    10 mg tablets30 tablets
    25 mg tablets30 tablets
    Day-supply limit30 days for each strength
    Documentation Required

    Bronchiectasis Documentation

    For the non-cystic fibrosis bronchiectasis indication, document a diagnosis supported by a clinical history consistent with bronchiectasis and computed tomography confirmation.

    • Clinical history may include cough, chronic sputum production, or recurrent respiratory exacerbations.
    • Document at least two pulmonary exacerbations requiring an antibiotic prescription within the past 12 months, or, for a pediatric patient, at least one such exacerbation within the past 12 months.
    • Document that the patient does not have cystic fibrosis, primary or secondary immunodeficiency, non-tuberculous mycobacterial disease, allergic bronchopulmonary aspergillosis, or tuberculosis.
    Documentation Required

    Indication and Age Support

    When approval is requested for another FDA-labeled indication, document the indication and route of administration. The patient’s age must be within FDA labeling, or supporting evidence must be provided for use in the patient’s age group.

    • Identify the applicable FDA-labeled indication for the requested agent and route.
    • Provide age-related labeling support when the patient is outside the FDA-labeled age range.
    Documentation Required

    Specialist Involvement

    The prescriber must be a specialist in the area of the patient’s diagnosis, such as a pulmonologist, or must provide evidence that a relevant specialist was consulted.

    • Document the prescriber’s specialty or the consulting specialist’s name and specialty.
    • Specialist involvement applies to initial and renewal authorization.
    Documentation Required

    Renewal Documentation

    Renewal requests must document clinical benefit with the requested agent and evidence of prior approval through the plan’s Prior Authorization process.

    • Include the patient’s response to therapy or other clinical evidence of benefit.
    • If the patient was not previously approved through the plan’s Prior Authorization process, submit the request for initial evaluation instead.
    Documentation Required

    Quantity-Limit Exception Documentation

    A quantity-limit exception may be requested when the requested quantity or dose exceeds the program quantity limit. Submit documentation supporting the higher dose and, when applicable, why the dose cannot be achieved with a lower quantity of a higher-strength product within the limit.

    • If there is no maximum FDA-labeled dose for the indication, provide support for therapy with the higher dose.
    • If the requested dose does not exceed the maximum FDA-labeled dose, document why it cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit.
    • If the requested dose exceeds the maximum FDA-labeled dose, provide support for therapy with the higher dose for the indication.
    Denial Risk

    Failure to Meet Clinical Criteria

    Authorization may be denied when the requested agent does not meet the applicable approved-indication, clinical, age, specialist, or safety requirements, or when required prior approval or renewal evidence is missing.

    • Deny when the patient lacks a qualifying FDA-labeled indication or does not meet the applicable initial or renewal criteria.
    • Deny when required specialist prescribing or consultation is not documented.
    • Deny when the patient has an FDA-labeled contraindication or when a renewal request lacks prior plan approval or documented clinical benefit.
    Denial Risk

    Bronchiectasis Criteria Not Met

    The bronchiectasis pathway may be denied when the diagnosis is not adequately documented or CT confirmation is absent, or when the required clinical history and exacerbation criteria are not met.

    • Deny when the patient does not have non-cystic fibrosis bronchiectasis supported by a consistent clinical history and CT confirmation.
    • Deny when the required number of antibiotic-treated pulmonary exacerbations within the past 12 months is not documented, including the applicable pediatric criterion.
    • Deny when cystic fibrosis, primary or secondary immunodeficiency, non-tuberculous mycobacterial disease, allergic bronchopulmonary aspergillosis, or tuberculosis is present.
    Denial Risk

    Quantity-Limit Exception Unsupported

    A quantity-limit exception may be denied when the requested quantity or dose exceeds the program limit without adequate clinical support or when the requested dose could be achieved within the limit using a lower quantity of a higher-strength product.

    • Deny when support for therapy with a higher dose is not provided.
    • Deny when the requested dose exceeds the maximum FDA-labeled dose without supporting documentation for the indication.
    • Deny when the request does not establish why a lower quantity of a higher strength within the program limit cannot achieve the requested dose.